2367 related articles for article (PubMed ID: 12668699)
1. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
[TBL] [Abstract][Full Text] [Related]
2. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
[TBL] [Abstract][Full Text] [Related]
3. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
[TBL] [Abstract][Full Text] [Related]
4. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
O'Keefe JH; Abuissa H; Pitt B
Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B
Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981
[TBL] [Abstract][Full Text] [Related]
6. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
Gheorghiade M; Khan S; Blair JE; Harinstein ME; Krum H; Mukherjee R; Pitt B;
Am Heart J; 2009 Sep; 158(3):437-43. PubMed ID: 19699868
[TBL] [Abstract][Full Text] [Related]
7. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
[TBL] [Abstract][Full Text] [Related]
8. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
Køber L; Torp-Pedersen C; Carlsen JE; Bagger H; Eliasen P; Lyngborg K; Videbaek J; Cole DS; Auclert L; Pauly NC
N Engl J Med; 1995 Dec; 333(25):1670-6. PubMed ID: 7477219
[TBL] [Abstract][Full Text] [Related]
9. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
Pitt B; White H; Nicolau J; Martinez F; Gheorghiade M; Aschermann M; van Veldhuisen DJ; Zannad F; Krum H; Mukherjee R; Vincent J;
J Am Coll Cardiol; 2005 Aug; 46(3):425-31. PubMed ID: 16053953
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
de Pouvourville G; Solesse A; Beillat M
Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835
[TBL] [Abstract][Full Text] [Related]
11. Adherence to aldosterone-blocking agents in patients with heart failure.
Margolis J; Gerber RA; Roberts C; Gheorghiade M
Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
[TBL] [Abstract][Full Text] [Related]
12. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
14. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
[No Abstract] [Full Text] [Related]
15. Eplerenone reduces morbidity and mortality after acute MI.
Cardiovasc J S Afr; 2006; 17(5):280. PubMed ID: 17117244
[No Abstract] [Full Text] [Related]
16. Review article: eplerenone: an underused medication?
Abuannadi M; O'Keefe JH
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
[TBL] [Abstract][Full Text] [Related]
17. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
[TBL] [Abstract][Full Text] [Related]
18. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
Rossignol P; Ménard J; Fay R; Gustafsson F; Pitt B; Zannad F
J Am Coll Cardiol; 2011 Nov; 58(19):1958-66. PubMed ID: 22032706
[TBL] [Abstract][Full Text] [Related]
19. Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS.
Ukena C; Dobre D; Mahfoud F; Kindermann I; Lamiral Z; Tala S; Rossignol P; Turgonyi E; Pitt B; Böhm M; Zannad F
J Card Fail; 2012 Jun; 18(6):439-45. PubMed ID: 22633301
[TBL] [Abstract][Full Text] [Related]
20. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
Barnes BJ; Howard PA
Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
